Fortress Biotech
FBIO
73 hedge funds and large institutions have $60.6M invested in Fortress Biotech in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 21 increasing their positions, 5 reducing their positions, and 10 closing their positions.
1,644% more capital inflows, than outflows
Capital inflows: $36M | Capital outflows: $2.06M
320% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 5
190% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 10
33% more funds holding
Funds holding: 55 → 73 (+18)
15.66% more ownership
Funds ownership: 11.74% → 27.4% (+16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$9.48M |
| 2 |
BlackRock
New York
|
+$8.55M |
| 3 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.43M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.08M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$684K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$366K |
| 3 |
Credit Suisse
Zurich,
Switzerland
|
-$320K |
| 4 |
Goldman Sachs
New York
|
-$307K |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$82K |
FBIO Hedge Fund Activity: Q2 2020 in Review
73 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q2 2020, worth a combined $60.6M — up 248% from $17.4M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new FBIO positions and 10 closed out — a net gain of 19 holders — while 21 added to existing stakes and 5 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $9.48M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $684K sold.
- 73 institutional investors held Fortress Biotech (FBIO) as of Q2 2020, up from 55 in Q1 2020.
- Funds reported $60.6M of Fortress Biotech stock for Q2 2020, up 248% quarter-over-quarter.
- 29 funds opened new Fortress Biotech positions in Q2 2020 and 10 closed out, a net change of +19 holders.
- The largest Fortress Biotech buyer in Q2 2020 was Opaleye Management, an estimated $9.48M added.
- The largest Fortress Biotech seller in Q2 2020 was Susquehanna International Group, an estimated $684K sold.
Based on aggregated 13F filings for Q2 2020.